Skip to main content
. Author manuscript; available in PMC: 2010 Dec 1.
Published in final edited form as: J Labelled Comp Radiopharm. 2009 Dec 1;52(14):583–590. doi: 10.1002/jlcr.1691

Figure 2.

Figure 2

Western blot showing the relative expression of (A) ErbB-2 (~ 185 kDa) in ovcar-3 and HIO-80 total cell lysates (40 μg each). Cytoplasmic marker α-tubulin (~ 50 kDa) was used to determine equal loading of proteins. (B) for determining the cell binding properties of 111In-labeled peptides, approximately 2.0 ×106 cells per tube were incubated at 37°C for different time intervals with 3.0 ×104cpm 111In-DOTA-GSG-KCCYSL or scrambled 111In-DOTA-GSG-KYLCSC (n=3 each time point). While 111In-DOTA-GSG-KCCYSL binding to human ovcar-3 carcinoma cells was observed, only minimal binding was seen with normal ovarian epithelial HIO-80 cells that express very little ErbB-2. 111In-DOTA-GSG-KYLCSC did not show significant binding to either ovcar-3 or HIO-80 cell lines.

HHS Vulnerability Disclosure